Diovan HCT Paragraph IV Certification Filed
This article was originally published in The Pink Sheet Daily
Executive Summary
The first ANDA with a Paragraph IV certification for Novartis' antihypertensive Diovan HCT (valsartan and hydrochlorothiazide) was filed Dec. 2, according to FDA's Feb. 6 updated list of filings